| Literature DB >> 34167859 |
Vicente Plaza1, Isam Alobid2, Cesáreo Alvarez3, Marina Blanco4, Jorge Ferreira5, Gabriel García6, Antonio Gómez-Outes7, Fernando Gómez8, Antonio Hidalgo9, Javier Korta10, Jesús Molina11, Francisco Javier Pellegrini12, Montserrat Pérez13, Javier Plaza14, Manuel Praena15, Santiago Quirce16, José Sanz17.
Abstract
In this fifth phase of development, the contents of the Spanish Asthma Management Guidelines (GEMA), which include versions 5.0 and 5.1, have undergone a thorough review. The aim here is to set the main changes in context. These could be summarized as follows: DIAGNOSIS: new FENO cut-off and severity classification based on treatment needed to maintain control; INTERMITTENT ASTHMA: a more restrictive concept and treatment extended to include a glucocorticoid/adrenergic combination as needed; MILD ASTHMA: glucocorticoid/adrenergic therapy as needed as an alternative in case of low therapeutic adherence to conventional fixed-dose steroids; SEVERE ASTHMA: readjustment of phenotypes, incorporation of triple therapy in a single inhaler, and criteria for selection of a biologic in severe uncontrolled asthma; OTHERS: specific scoring in childhood asthma, incorporation of certain organizational aspects (care circuits, asthma units, telemedicine), new sections on COVID-19 and nasal polyposis.Entities:
Keywords: Asma; Asthma; Clinical practice guidelines; Consenso; Consensus; Evidence-based medicine; Guía de práctica clínica; Medicina basada en la evidencia
Year: 2021 PMID: 34167859 DOI: 10.1016/j.arbres.2021.05.010
Source DB: PubMed Journal: Arch Bronconeumol ISSN: 0300-2896 Impact factor: 4.872